Gossel, L.D.H.; Heim, C.; Pfeffermann, L.-M.; Moser, L.M.; Bönig, H.B.; Klingebiel, T.E.; Bader, P.; Wels, W.S.; Merker, M.; Rettinger, E.
Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor. Cancers 2021, 13, 1443.
https://doi.org/10.3390/cancers13061443
AMA Style
Gossel LDH, Heim C, Pfeffermann L-M, Moser LM, Bönig HB, Klingebiel TE, Bader P, Wels WS, Merker M, Rettinger E.
Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor. Cancers. 2021; 13(6):1443.
https://doi.org/10.3390/cancers13061443
Chicago/Turabian Style
Gossel, Leonie D. H., Catrin Heim, Lisa-Marie Pfeffermann, Laura M. Moser, Halvard B. Bönig, Thomas E. Klingebiel, Peter Bader, Winfried S. Wels, Michael Merker, and Eva Rettinger.
2021. "Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor" Cancers 13, no. 6: 1443.
https://doi.org/10.3390/cancers13061443
APA Style
Gossel, L. D. H., Heim, C., Pfeffermann, L.-M., Moser, L. M., Bönig, H. B., Klingebiel, T. E., Bader, P., Wels, W. S., Merker, M., & Rettinger, E.
(2021). Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor. Cancers, 13(6), 1443.
https://doi.org/10.3390/cancers13061443